A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2002
11/20/2002	EP1002542B1 Use of vip for the preparation of a medicament for treating the endotoxic shock in mammals
11/20/2002	EP0929530B1 Quinazoline derivatives and pharmaceutical compositions containing them
11/20/2002	EP0847280B1 Compositions and their uses against hyperacute rejection of xenografts and certain diseases
11/20/2002	EP0833828B1 Rapamycin derivatives
11/20/2002	EP0826673B1 Acetamide derivatives, process for producing the same, and medicinal composition containing the same
11/20/2002	EP0750507B1 Proteasome regulation of nf-kappa-b activity
11/20/2002	CN1380298A Method for separating and extracting total flavone from goldenrain tree plant and its application
11/20/2002	CN1380101A Biological immunomodulator for preventing and curing mad cattle disease and its production method
11/20/2002	CN1380100A Biological immunomodulator for animal for curing and preventing foot and mouth disease and its production method
11/20/2002	CN1380099A Human body immunomodulator modulated by micro-alternating biological electric field and its preparation method
11/20/2002	CN1094365C Cordyceps-pollen health-care food and its preparing method
11/20/2002	CN1094364C Human placenta-pollen health-care food and its preparing method
11/20/2002	CN1094363C Ginseng-pollen health-care food and its preparing method
11/19/2002	US6482986 Benzene derivatives, preparation method and pharmaceutical compositions containing same
11/19/2002	US6482925 Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants
11/19/2002	US6482924 Leptospira vaccine antigens for the prevention of Leptospirosis
11/19/2002	US6482852 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
11/19/2002	US6482848 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
11/19/2002	US6482845 Method for inhibiting interleukin-2 production using tricyclo compounds
11/19/2002	US6482830 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
11/19/2002	US6482829 Central nervous system disorders; heeadaches, antiinflammatory agents
11/19/2002	US6482822 N-(iminomethyl)amines derivatives, their preparation, their use as medicines and compositions containing them
11/19/2002	US6482812 Method of locking 1α-OH of vitamin D compounds in axial orientation
11/19/2002	US6482618 Self-enhancing, pharmacologically controllable expression systems
11/19/2002	US6482614 Stress proteins and uses therefor
11/19/2002	US6482610 Method for producing agents for treating tumor diseases and for immunosuppression
11/19/2002	US6482421 Pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation, hypersensitivity reactions or pain
11/19/2002	US6482407 Membrane-bound cytokine compositions comprising GM-CSF or an active fragment thereof and methods of modulating and an immune response using the same
11/19/2002	US6482405 Antitumor
11/19/2002	US6481435 Closure-cap and container as a two-chamber cartridge for nebulizers for producing aerosols and active substance formulations, suitable for storage
11/19/2002	CA2332631C Soft gelatin capsule manufacture
11/19/2002	CA2312667C Novel cytokine
11/19/2002	CA2272990C Heptapeptide oxytocin analogues
11/19/2002	CA2261579C Isolated peptides derived from mage-2
11/19/2002	CA2252513C Method for the prevention and treatment of cachexia and anorexia
11/19/2002	CA2086101C Immune suppressive product from milk
11/19/2002	CA2061706C Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis
11/14/2002	WO2002090981A1 Antitumor antigen against htlv-1 tumor or antigen epitope thereof
11/14/2002	WO2002090566A2 Recombinant tumor specific antibody and use thereof
11/14/2002	WO2002090553A2 Recombinant fusion proteins and the trimers thereof
11/14/2002	WO2002090542A2 Antigenic epitopes of factor viii, inhibitors directed against said epitopes and use thereof
11/14/2002	WO2002090530A2 Kinases and phosphatases
11/14/2002	WO2002090524A2 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
11/14/2002	WO2002090504A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
11/14/2002	WO2002090375A2 Liver x receptor agonists
11/14/2002	WO2002090355A1 N-aroyl cyclic amines
11/14/2002	WO2002090352A2 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
11/14/2002	WO2002090349A1 N-oxide anthranylamide derivatives and their use as medicaments
11/14/2002	WO2002090330A1 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives
11/14/2002	WO2002090317A1 Substituted cyclohexane-1,4-diamine derivatives
11/14/2002	WO2002089832A2 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
11/14/2002	WO2002089796A2 Methods for selective immunomodulation using pimecrolimus
11/14/2002	WO2002089783A1 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties
11/14/2002	WO2002089773A2 Pharmaceutical compositions comprising cyclosporin
11/14/2002	WO2002089747A2 Compositions and methods for the therapy and diagnosis of prostate cancer
11/14/2002	WO2002064616A3 Agonists and antagonists of sphingosine-1-phosphate receptors
11/14/2002	WO2002064550A8 Glucocorticoid receptor modulators
11/14/2002	WO2002062370A3 Stabilization of hypoallergenic, hyperdigestible previously reduced proteins
11/14/2002	WO2002051233A3 Universal antimicrobial treatment
11/14/2002	WO2002049634A3 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
11/14/2002	WO2002028906A3 Regulation of human sphingosine kinase-like protein
11/14/2002	WO2002018623A3 Methods and reagents for protease inhibition
11/14/2002	WO2002018404A3 Nucleoside derivatives for the treatment of hepatitis c
11/14/2002	WO2002009746A8 Vaccines comprising outer membrane vesciles from gram negative bacteria
11/14/2002	US20020169336 Able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders
11/14/2002	US20020169326 Fatty acid derivatives
11/14/2002	US20020169314 Sulfonamide derivative as a matrix metalloproteinase inhibitor
11/14/2002	US20020169203 Modulators of all three classes of calcium channel blocker subtypes (Small, Intermediate and Big conductance K channel (SK, IK and BK)) comprising malonate esters and nitriles; respiratory, brain, cardiovascular, urogenital disorders
11/14/2002	US20020169183 Acridines as stimulators for Fas-mediated apoptosis
11/14/2002	US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002	US20020169174 Xanthine phosphodiesterase V inhibitors
11/14/2002	US20020169171 Alkoxycarbonylamino heteroaryl carboxylic acid derivatives as IP antagonists
11/14/2002	US20020169164 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
11/14/2002	US20020169159 An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020169140 Minimising dosage required of chemotherapeutic agents for their use in antiviral, antibacterial, antiparasitic and anticancer chemotherapy; for treating neoplasms and tumours, viral, bacterial, or parasite infections
11/14/2002	US20020169133 Treatment of diseases characterized by excessive deposits of fibrillar interstitial collagens that are resistant to proteolyic degradation thus leading to symptoms of fibrosis
11/14/2002	US20020169131 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002	US20020169117 (RANK); RANK is a member of the TNF superfamily; used to regulate an immune response
11/14/2002	US20020169114 Formulation of boronic acid compounds
11/14/2002	US20020168782 Apparatus for use inthe detection of allergen preferential immunoglobulin in sample
11/14/2002	US20020168754 Nucleotide sequences coding polypeptides for use in the treatment of gastric, testicular, retinal, nervous system and immunological disorders
11/14/2002	US20020168716 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of tumors, immunological, autoimmune, skin, viral, bone, nervous system and inflammatory disorders
11/14/2002	US20020168712 Molecules designated LDCAM
11/14/2002	US20020168631 Random gene unidirectional antisense library
11/14/2002	US20020168415 Biocompatible; culture product; anticancer agents
11/14/2002	US20020168397 Antiallergens, antiinflammatory agents; oral administering
11/14/2002	US20020168388 Topical cosmetic composition
11/14/2002	US20020168385 Adeno-associated virus vector for boosting immunogenicity of cells
11/14/2002	US20020168383 Modifications of antigens by the introduction of aldehyde groups and their use in enhancing the immune response
11/14/2002	US20020168380 Moderating immunology response
11/14/2002	US20020168376 Plant extracts; sensitization of an animal; screening
11/14/2002	US20020168374 Hla binding peptides and their uses
11/14/2002	US20020168373 House dust mite allergen, Der f VII, and uses therefor
11/14/2002	US20020168362 Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
11/14/2002	US20020168360 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
11/14/2002	US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002	US20020168352 A C1 esterase inhibitor (C1-INH) for preventing or delaying hyperacute and/or acute rejection of xenotransplants in mammals
11/14/2002	DE10119680A1 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation Use of scavenger compounds for the treatment and prevention of no-dependent disorders of microcirculation
11/14/2002	CA2453223A1 Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors

1 ... 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 ... 1172